Kentucky Bioprocessing Selects Meridian Clinical Research to Conduct Phase I Influenza Vaccine Clinical Trial of KBP-V001

Kentucky Bioprocessing Selects Meridian Clinical Research to Conduct Phase I Influenza Vaccine Clinical Trial of KBP-V001

Kentucky Bioprocessing (KBP) (owned by British American Tobacco) recently launched a clinical trial to test its seasonal flu vaccine candidate. Working with research site organization Meridian Clinical Research, the sponsor and principal investigator will be targeting 120 volunteers in Omaha, Nebraska. A world leader in using tobacco and other plants to produce pharmaceuticals and other high value products, the company is focused on developing standardized templates to produce highly effective vaccines that target a wide variety of diseases, while meeting stringent regulatory requirements for process and production control. After two years of preliminary work, the company has progressed to the Phase I clinical trial for the investigational influenza vaccine called KBP-V001.

The Investigational Vaccine Candidate

Back in April 2020, TrialSite News introduced Kentucky Bioprocessing (owned by British American Tobacco) and their effort to develop a COVID-19 vaccine. In May, Genetic Engineering & Biotechnology News updated the market that the COVID-19 vaccine was still in preclinical.

Now an investigational influenza vaccine know...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee